Boston Scientific Co. (NYSE:BSX) Shares Acquired by Shell Asset Management Co.

Shell Asset Management Co. lifted its position in shares of Boston Scientific Co. (NYSE:BSX) by 32.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,120 shares of the medical equipment provider’s stock after buying an additional 5,626 shares during the quarter. Shell Asset Management Co.’s holdings in Boston Scientific were worth $2,065,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider’s stock worth $11,869,805,000 after buying an additional 1,600,062 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Boston Scientific by 10.2% during the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock worth $3,230,293,000 after buying an additional 3,344,571 shares during the last quarter. Geode Capital Management LLC raised its stake in Boston Scientific by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider’s stock valued at $2,729,371,000 after purchasing an additional 1,041,329 shares during the last quarter. Capital World Investors raised its stake in Boston Scientific by 28.7% in the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Boston Scientific by 2.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider’s stock valued at $1,992,994,000 after purchasing an additional 554,388 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.1%

Shares of NYSE:BSX opened at $106.00 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a 1 year low of $71.88 and a 1 year high of $107.17. The stock has a market capitalization of $156.83 billion, a P/E ratio of 84.80, a PEG ratio of 2.79 and a beta of 0.68. The stock has a 50-day simple moving average of $99.18 and a 200-day simple moving average of $96.57.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The business had revenue of $4.66 billion during the quarter, compared to analysts’ expectations of $4.57 billion. During the same quarter in the previous year, the business earned $0.56 EPS. The company’s revenue for the quarter was up 20.9% on a year-over-year basis. Equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on BSX shares. Evercore ISI boosted their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Argus set a $130.00 target price on shares of Boston Scientific in a research note on Tuesday, February 18th. BTIG Research reissued a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, April 23rd. Citigroup boosted their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, Royal Bank of Canada boosted their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Twenty-three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $114.74.

Insider Transactions at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the company’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares of the company’s stock, valued at $3,441,592.37. This represents a 11.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 2,657 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $104.41, for a total value of $277,417.37. Following the completion of the transaction, the executive vice president now directly owns 24,294 shares in the company, valued at approximately $2,536,536.54. The trade was a 9.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 265,820 shares of company stock worth $27,406,958. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.